Neurexis Therapeutics

Recent Finacing

Grant

Recent Raise

$3M

Neurexis Therapeutics develops the neuroprotective peptide tatCN19o targeting CaMKII to prevent neuronal death and functional deficits after ischemia, testing efficacy in small and large animal models toward clinical translation.